Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea

TerminatedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 7, 2018

Primary Completion Date

April 14, 2020

Study Completion Date

April 14, 2020

Conditions

Submental Fullness

Interventions

DRUG

BELKYRA Inj.

Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.

Trial Locations (4)

Oracle-Dermatology, Daejeon

Goldenview plastic surgery, Seoul

(Apgujeong) Oracle-Dermatology, Seoul

Dream-Dermatology, Seoul